Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
HOME > REGULATORY
REGULATORY
- ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials
January 24, 2020
- Japan Approved World’s 1st Topical JAK Inhibitor Delgocitinib, and More
January 24, 2020
- PMDA to Provide Information Free of Charge for Drug Makers to Consider Use of MID-NET Starting in April
January 24, 2020
- Chuikyo OKs New Drug Pricing Rules for 2020 Reform
January 23, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
- Get Serious about Reviewing Scope of Health Coverage, Says MOF Budget Examiner
January 22, 2020
- Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
- MHLW Orders Label Revisions for Suglat, Sujanu, and More
January 22, 2020
- Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
- MHLW Bureau Chief Urges Prefectural Officials to Up Monitoring Efforts after GMP Lapses Found
January 21, 2020
- MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
- Takeda’s RCC Drug Cabometyx in MHLW Panel’s Review Roster for January 29; Alecensa, Opdivo and More
January 16, 2020
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
- HIV Meds Dovato, Pifeltro to Join NHI Price List on January 22
January 16, 2020
- Australia to Provide Expedited Reviews for OTC and Quasi-Drugs Approved in Japan
January 16, 2020
- Rotavirus Vaccine to Be Included in Public Vaccination Programs Starting Oct. 1
January 16, 2020
- Novartis’ Eylea Contender Up for MHLW Panel Review on January 27
January 15, 2020
- Japan Approves 2 HIV Drugs, Listing Expected Soon
January 15, 2020
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Osaka Univ. Professor, Mitsubishi Tanabe Receive Prime Minister’s R&D Award for Contributions to Development of SGLT2 Inhibitor
January 14, 2020
ページ
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Combined sales of eight major Japanese drug makers grew nearly 26% year on year in April-September, pushed up by the acquisition of Shire by Takeda Pharmaceutical. Even excluding the industry leader, though, seven firms still collectively eked out a slight…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…